Lanean...
Dual Antiplatelet Therapy Beyond 90 Days in Symptomatic Intracranial Stenosis in the SAMMPRIS Trial
BACKGROUND: The safety and efficacy of dual antiplatelet use for symptomatic intracranial atherosclerosis beyond 90 days is unknown. Data from SAMMPRIS was used to determine if dual antiplatelet therapy (DAPT) beyond 90 days impacted the risk of ischemic stroke and hemorrhage. METHODS: This post hoc...
Gorde:
| Argitaratua izan da: | J Stroke Cerebrovasc Dis |
|---|---|
| Egile Nagusiak: | , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7686095/ https://ncbi.nlm.nih.gov/pubmed/32992190 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2020.105254 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|